Share on StockTwits

Repros Therapeutics (NASDAQ:RPRX)‘s stock had its “positive” rating reiterated by equities research analysts at Ascendiant Capital Markets in a research note issued to investors on Friday.

The analysts wrote, “We believe that the positive result from the ZA-305 study bodes well for a positive result from the ZA-304 study, given that the trials are identical in design. Further, we believe that positive results from these studies will also be valuable in supporting potential labeling claims for superiority of Androxal over Androgel, which would improve the commercial attractiveness of the product. Our 12 month PT is calculated using an NPV analysis.”

Repros Therapeutics (NASDAQ:RPRX) opened at 21.58 on Friday. Repros Therapeutics has a 52 week low of $12.61 and a 52 week high of $29.79. The stock’s 50-day moving average is $15. and its 200-day moving average is $16.73. The company’s market cap is $498.7 million.

Repros Therapeutics (NASDAQ:RPRX) last announced its earnings results on Monday, August 11th. The company reported ($0.38) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.37) by $0.01. Analysts expect that Repros Therapeutics will post $-1.53 EPS for the current fiscal year.

Repros Therapeutics, Inc is a United States-based company that develops products and services for the management of reproductive health.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.